Blueprint Medicines Corp (NAS:BPMC)
$ 96.53 -1.09 (-1.12%) Market Cap: 6.13 Bil Enterprise Value: 5.94 Bil PE Ratio: 0 PB Ratio: 19.54 GF Score: 81/100

Blueprint Medicines Corp Research and Development Day with Q3 2019 Blueprint Medicines Corp Earnings Call Transcript

Nov 05, 2019 / 01:30PM GMT
Release Date Price: $70.5 (+5.04%)
Jeffrey W. Albers
Blueprint Medicines Corporation - CEO, President & Director

Okay, I think we'll get started here. I'm Jeff Albers. I am the CEO of Blueprint Medicines. And on behalf of all of our employees, I want to welcome those of you in the room here in New York City with us as well as those participating on the webcast.

Today marks an exceptional moment in time for us at Blueprint Medicines as we sit on the cusp of bringing our 2 lead programs, avapritinib and pralsetinib, directly to patients and with pending and planned regulatory filings in the near term. But with our long term strategy, it's truly grounded in transformational science and the discovery and development of new targets. And that's going to be our focus of our time together today.

And in that spirit, we have a lot to share. You're going to hear about 4 newly disclosed programs out of our pipeline. We're going to introduce you to our latest thinking on the number of patients with systemic mastocytosis, a number that could be 3 to 4x higher than what we've talked about or estimated previously. And then we're

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot